Probes for chemical genomics by design.
Chemical genomics represents a convergence of biology and chemistry in the era of global approaches to target identification and intervention. The success of genomics has led to a bottleneck in target validation that could be overcome by using small diverse organic compounds to interfere with biological processes. Because of the limitations of existing compound collections, this diversity can only fully be exploited using in silico design techniques to guide the selection of molecules with optimal binding properties. Structure-based design is used to create structures de novo that can be synthesized for use as chemical probes and drug leads.
De Nove Pharmaceuticals, Compass House, Vision Park, Histon, Cambridge, UK CB4 9ZR. ed.zanders@denovopharma.com
Edward D
ED
Zanders
David S
DS
Bailey
Philip M
PM
Dean
D000595:Amino Acid Sequence; D016282:Aspartic Acid Endopeptidases / Q000737:chemistry; D001695:Biology / Q000639:trends; D002621:Chemistry / Q000639:trends; D015195:Drug Design; D023281:Genomics; D006801:Humans; D008968:Molecular Conformation; D008969:Molecular Sequence Data; D004364:Pharmaceutical Preparations / Q000737:chemistry; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid
D004364:Pharmaceutical Preparations; D016282:Aspartic Acid Endopeptidases